Observational studyAdvances in rheumatology (London, England)2025
A real-life study of juvenile idiopathic arthritis from two Brazilian referral centers for pediatric rheumatology.
Observational study in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, but its outcomes are still difficult to determine. We aimed to obtain outcome measurements of disease activity, functional capacity, disease damage, and therapeutic response, at one-year follow-up study on a real-life basis.
methodsAn observational JIA cohort from two referral centers for pediatric rheumatology in Brazil Pediatric Rheumatology Centers was carried out over a period of one year. Clinimetric validated outcome measurements were applied over four visits. Multivariable logistic regression was performed to evaluate baseline variables associated with the following outcomes after one year of follow-up: disease activity, Minimal Disease Activity (MDA), disease flare, remission on medication and remission off medication.
resultsA total of 127 patients were included in the study. Eighty-three (65.4%) were females, and median time to diagnosis was 6.0 months. JADAS71 and CHAQ improved during follow-up (mean Vbaseline 7.05 ± 9.3 vs. V52 3.52 ± 8.4; 0 ± 0.5 vs. 0.14 ± 0.4, p < 0.001, respectively) as well as JIA-ACR 30, 50, 70 and 90 (Vbaseline 79.8% vs. V52 88.8%; 71.4% vs. 84.1%; 59.7% vs. 77.6%; 49.6% vs. 69.2%, p < 0.05, respectively). Inactive disease was present in 33% of patients at baseline and in 67.9% at V52 (p < 0.001). Remission on medication, remission off medication and MDA were present in 46%, 11%, and 80.6% of patients at V52, respectively. Extra-articular and articular damage were not common at baseline (0.3 ± 0.7 and 1.1 ± 3.4 respectively) and did not decrease significantly during the period of the study. The presence of active joints 46/101 (45.5%) at baseline reduced the chance of the patient achieving remission off medication at the last visit by 84% (OR = 0.16; CI 95% from 0.03 to 0.91, p = 0.039).
conclusionThis study showed improvement in clinimetric outcome measurements and therapeutic responses in an inception cohort of JIA patients. The presence of active joints at baseline is related to not achieving remission at last visit. Long-term prospective and multicenter studies are needed to better assess the outcome of JIA and the differences among JIA subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.